Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension Source: Eur Respir J 2001; 18: 838-845 Year: 2001
Effects of keratinocyte growth factor (KGF) on matrix metalloproteinases (MMPs) & tissue inhibitors of metalloproteinases (TIMPs) mRNA levels in emphysematous rats lungs Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo Source: Eur Respir J 2002; 20: 170-176 Year: 2002
Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD. Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Role of matrix metalloproteinases in progression of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010
Matrix metalloproteinase (MMP) 9 is associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Remodelling of extracellular matrix (ECM) differs between pulmonary adenocarcinoma (Ad) and squamous cell carcinoma (Sq): immunohistochemistry and morphometry of matrix proteins (MPs), matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs (TIMPs Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008
Matrix metalloproteinase (MMP) 12 is not associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
Expression of elastolytic matrix metalloproteinases in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 228s Year: 2002
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
The genetic polymorphism of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011
Matrix metalloprotease-1 and tissue inhibitor of metalloprotease-1 levels in pleural effusions of different origins Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Matrix metalloproteinases and their inhibitors in pulmonary hypertension}, Source: Eur Respir J 2012; 40: 766-782 Year: 2012